GLP-1 Pill Cuts Weight 12%; U.S. Measles Sets 35-Year Record; Brain Immunity Shifts at 50

Oral aleniglipron achieves 12% weight loss; U.S. measles hits a 35-year high; a wearable REM patch; brain immunity rewires at midlife.

• June–August 2026: Oral GLP-1 Drug Aleniglipron Achieves 12% Weight Loss in Phase 2b Trial
• August 2026: U.S. Measles Cases Hit a 35-Year High, Threatening Elimination Status
• August 2026: Wearable Ultrasound Patch Gets Sleepers into REM 43 Minutes Faster
• August 2026: The Brain's Hippocampal Immune Cells Quietly Rebuild — and Inflame — Starting at 50